Nurtec ODT - (75 mg ; Orally Disintegrating Tablets)

Generic Name	Rimegepant Sulfate	Innovator	Pfizer
Dosage	75 mg ; Orally Disintegrating Tablets	Branded US Sales	Less Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults • preventive treatment of episodic migraine in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** \ *********	*** **, ****	*******	****	*** ****** *** **** (******** ******)
*********	*** \ *********	*** **, ****	*******	****	*** ****** *** **** (******** ******)
********* ******	*** \ *********	*** **, ****	*******	****	*** ****** *** **** (******** ******)

Chronology Of Events